Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2017 | Mavupharma | Series A | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 11/2020 | Inipharm | Series A | 0 |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 3/2019 | Scout Bio | Series B | 20M |
| 12/2007 | PowerVision | Series B | 20M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 6/2008 | EBR Systems | Series C | 35M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 8/2000 | PatientKeeper | Series B | 0 |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 8/2008 | Calibra Medical | Series B | 35M |
| 2/2007 | Chimerix | Series D | 23.1M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 6/2005 | Cierra | Funding Round | 21M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 10/2003 | Cotherix | Series C | 55M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 8/2009 | Barosense | Series D | 27M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 7/2013 | Alcresta | Series B | 10M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 6/2003 | Xoft | Series B | 0 |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 4/2007 | Xoft | Series D | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 3/2020 | Amunix | Series A | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 4/2008 | Stromedix | Series B | 25M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 3/2006 | PowerVision | Series A | 2M |
| 9/2021 | HilleVax | Equity | 135M |
| 2/2021 | Seraxis | Series C | 40M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 2/2007 | Pivot Medical | Series A | 2M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 12/2003 | FlowCardia | Series B | 12M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 3/2009 | Stemgent | Series B | 14M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 9/2002 | Glaukos | Series A | 10M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 1/2014 | PowerVision | Series D | 0 |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 3/2021 | Amunix | Series B | 117M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 1/1996 | Corixa | Venture Round | - |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 8/2007 | FlowCardia | Series C | 0 |
| 6/2006 | PatientKeeper | Series E | 0 |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 1/2005 | PowerVision | Series A | 4.4M |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 4/2012 | Alcresta | Series A | 10M |
| 3/2007 | Stromedix | Series A | 1M |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 12/2007 | Pivot Medical | Series B | 0 |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 5/2016 | Aptinyx | Series A | 0 |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 1/1998 | Array BioPharma | Venture Round | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 1/2000 | Simpata Inc | Series B | 20M |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 5/2007 | CVRx | Series D | 65M |
| 1/1996 | ViroPharma | Funding Round | - |
| 7/2011 | PowerVision | Series C | 24M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 12/2007 | Barosense | Series C | 11.2M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
